Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) EVP Charles Wagner, Jr. sold 15,286 shares of the firm’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $547.87, for a total value of $8,374,740.82. Following the completion of the sale, the executive vice president owned 31,764 shares in the company, valued at $17,402,542.68. The trade was a 32.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Stock Down 0.7%
Vertex Pharmaceuticals stock opened at $534.20 on Wednesday. The company has a 50-day simple moving average of $522.31 and a 200-day simple moving average of $484.43. The firm has a market capitalization of $135.44 billion, a P/E ratio of 31.62, a P/E/G ratio of 2.85 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34. Vertex Pharmaceuticals Incorporated has a one year low of $412.27 and a one year high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the business earned $4.80 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals News Summary
Investors following VRTX have been watching these news items:
- Positive Sentiment: A comparison of healthcare stocks highlights Vertex’s dominant cystic fibrosis business and expansion into gene therapies as potential growth drivers. Johnson & Johnson vs. Vertex article
- Neutral Sentiment: Vertex presented at the Jefferies Global Healthcare Conference, but the available article entry does not detail announcements that would change its outlook. Jefferies conference transcript
- Negative Sentiment: EVP Charles Wagner sold 15,286 shares for about $8.4 million, reducing his direct holdings by 32.49%. The trade was made under a pre-arranged Rule 10b5-1 plan, which makes it a less direct signal of a change in his view of the company. Insider sale details
Hedge Funds Weigh In On Vertex Pharmaceuticals
Several large investors have recently bought and sold shares of the stock. Summit Global Investments bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $3,568,000. Danica Pension Livsforsikringsaktieselskab bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth $13,823,000. UNIVEST FINANCIAL Corp bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth $4,495,000. State Street Corp raised its holdings in Vertex Pharmaceuticals by 1.2% in the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after acquiring an additional 141,320 shares during the period. Finally, Meeder Advisory Services Inc. acquired a new position in Vertex Pharmaceuticals during the 2nd quarter worth $3,187,000. Institutional investors and hedge funds own 90.96% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
